Melanotan II: adverse events and evidence limits
A two-week subcutaneous Melanotan-II pilot in three healthy men described nausea, somnolence, fatigue and spontaneous erections lasting 1–5 hours. [1]
This small dose-escalation sample cannot establish risk frequencies for another preparation. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Nausea | Three healthy men, subcutaneous Melanotan-II, two-week dose-escalation pilot | Described; the small sample cannot establish a frequency | [1] |
| Somnolence | The same participants | Described; no frequency given | [1] |
| Fatigue | The same participants | Described; no frequency given | [1] |
| Spontaneous erections lasting 1–5 hours | The same participants | Described; no frequency given | [1] |
References
- R T Dorr et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study https://doi.org/10.1016/0024-3205(96)00160-9.